Global Cord Blood Corporation (CORBF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Global Cord Blood Corporation (CORBF) trades at $0.95 with AI Score 53/100 (Grade B). Global Cord Blood Corporation operates three cord blood banks in China, providing umbilical cord blood storage and ancillary services. Market cap: $127.35M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for CORBF: CORBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CORBF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CORBF: 4/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Global Cord Blood Corporation (CORBF) Healthcare & Pipeline Overview
Global Cord Blood Corporation is a specialized healthcare provider operating three licensed cord blood banks in the Beijing municipality, Guangdong province, and Zhejiang province of the People's Republic of China. The company delivers essential umbilical cord blood testing, processing, and long-term storage services for both private subscribers and public donation programs, establishing its niche in the burgeoning Chinese healthcare market.
What Is the Investment Thesis for CORBF?
Global Cord Blood Corporation presents an investment profile characterized by its established niche in the specialized Chinese cord blood banking sector. The company's financial metrics, including a P/E ratio of 1.6, a robust profit margin of 40.3%, and an impressive gross margin of 85.3%, indicate strong operational efficiency and profitability within its defined market. Its market capitalization stands at $0.13 billion. The core value driver stems from the increasing awareness and adoption of cord blood banking services among China's populace, driven by advancements in regenerative medicine and a growing emphasis on personalized healthcare. As one of the licensed operators in specific high-density regions, Global Cord Blood Corporation benefits from a relatively protected market position. Potential growth catalysts include the ongoing expansion of its subscriber base within its existing licensed territories and the potential for regulatory-approved service diversification, although specific plans are not disclosed. The company's negative Beta of -0.81 suggests a historical inverse relationship with broader market movements, potentially offering a degree of portfolio diversification. However, investors must consider the inherent risks associated with its concentrated geographic operations in China and the regulatory landscape governing the healthcare sector.
Based on FMP financials and quantitative analysis
CORBF Key Highlights
- Market capitalization of $127.35M, reflecting its valuation within the specialized healthcare sector.
- A P/E ratio of 1.6, indicating a low earnings multiple relative to its profitability.
- Achieved a profit margin of 40.3%, demonstrating strong net income generation from its revenues.
- Maintained a gross margin of 85.3%, highlighting efficient cost management in its core service delivery.
- Operates three licensed cord blood banks as of March 31, 2022, strategically located in Beijing, Guangdong, and Zhejiang provinces.
Who Are CORBF's Competitors?
CORBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| AKU Akumin Inc. | $0.29 | -17.87% | $26.27M | 53 |
| CLIFF Cordlife Group Limited | $0.15 | +0.00% | $38.57M | 53 |
| CEMI Chembio Diagnostics, Inc. | $0.46 | +0.22% | $16.71M | 53 |
| CSTL Castle Biosciences, Inc. | $24.45 | +1.39% | $741.42M | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CORBF's Key Strengths?
- Established presence and operational licenses in key Chinese provinces (Beijing, Guangdong, Zhejiang).
- Strong financial performance with high gross margin (85.3%) and profit margin (40.3%).
- Specialized infrastructure and expertise in cord blood testing, processing, and storage.
- Dual business model serving both private subscribers and public donation programs.
What Are CORBF's Weaknesses?
- Geographic concentration of operations solely within the People's Republic of China, exposing it to country-specific risks.
- Reliance on a highly regulated industry with potential for policy changes impacting operations.
- Limited public disclosure status as an OTC-listed company, potentially affecting investor confidence and liquidity.
- Unknown details regarding CEO's specific track record and tenure, limiting leadership assessment.
What Could Drive CORBF Stock Higher?
- Continued operation of its three licensed cord blood banks in the Beijing municipality, Guangdong province, and Zhejiang province, serving its subscriber base.
- Sustained provision of comprehensive cord blood testing, processing, and long-term storage services to private subscribers.
- Active management of donated cord blood units and the provision of matching services to medical institutions in the People's Republic of China.
What Are the Key Risks for CORBF?
- **Regulatory Changes in China:** The company's operations are entirely within the People's Republic of China, making it highly susceptible to changes in healthcare regulations, licensing requirements, or policies governing biological sample storage and stem cell research, which could impact its business model or profitability.
- **Geographic Concentration:** All of Global Cord Blood Corporation's operations are concentrated in three specific provinces/municipalities in China. This geographic concentration exposes the company to localized economic downturns, public health crises, or regional policy shifts that could disproportionately affect its revenue and operational stability.
- **Competition within Licensed Regions:** While operating in a regulated market, the company still faces competition from other licensed cord blood banks within its operational regions. Intense competition could lead to pricing pressures, increased marketing costs, or a slower expansion of its subscriber base.
- **Operational Risks of Biological Storage:** The business inherently involves the long-term storage and preservation of sensitive biological materials. Risks include potential equipment failures, natural disasters, or human error that could compromise stored samples, leading to significant reputational damage and potential legal liabilities.
- **OTC Market Risks:** As an OTC-listed company with an 'Unknown' disclosure status, CORBF faces risks related to lower liquidity, wider bid-ask spreads, and potentially less transparent financial reporting, which can impact investor confidence and the ease of trading shares.
What Are the Growth Opportunities for CORBF?
- **Expansion of Subscriber Base within Licensed Regions:** Global Cord Blood Corporation has an opportunity to deepen its market penetration within its existing licensed operational areas, namely Beijing, Guangdong, and Zhejiang provinces. As awareness of the long-term health benefits of cord blood banking continues to grow among prospective parents in China, the company can capitalize on this trend by enhancing its marketing and educational outreach programs. Focusing on increasing the number of private subscribers for cord blood storage services within these high-population density regions represents a direct and quantifiable growth driver, leveraging its established infrastructure and operational licenses. This organic growth strategy relies on demographic trends and public health education initiatives.
- **Leveraging Advancements in Regenerative Medicine:** The broader field of regenerative medicine and stem cell research is continually evolving, presenting a significant long-term growth opportunity for Global Cord Blood Corporation. As new therapeutic applications for hematopoietic stem cells derived from cord blood are discovered and gain clinical acceptance, the perceived value and utility of cord blood storage services will likely increase. This could lead to higher demand for both private banking and public donation services. The company can position itself to benefit from these scientific breakthroughs by maintaining state-of-the-art storage and processing technologies, potentially collaborating with research institutions, and adapting its service offerings to align with emerging medical treatments.
- **Strategic Partnerships and Collaborations:** Forming strategic partnerships with hospitals, maternity clinics, and healthcare networks within its licensed provinces could significantly enhance Global Cord Blood Corporation's reach and customer acquisition channels. Collaborations could involve direct referral programs, co-marketing initiatives, or integration of cord blood banking education into prenatal care programs. Such partnerships would allow the company to more effectively engage with its target demographic at critical decision-making points, streamlining the process for prospective subscribers and potentially expanding its market footprint without requiring new provincial licenses.
- **Enhancement of Ancillary Services and Technology:** Beyond core storage, Global Cord Blood Corporation has an opportunity to enhance and diversify its ancillary services. This could involve investing in advanced genetic screening services for cord blood samples, offering more sophisticated retrieval and preparation services for therapeutic use, or integrating digital platforms for subscriber management and educational resources. Continuous technological upgrades in processing and storage techniques, such as improved cryopreservation methods or automation, could also enhance efficiency, reduce operational costs, and improve service quality, thereby attracting and retaining a larger client base in a competitive market.
- **Increased Public Awareness and Education:** A sustained and targeted effort to increase public awareness regarding the importance and benefits of umbilical cord blood banking, both for private use and public donation, represents a foundational growth opportunity. Many potential subscribers may still be unfamiliar with the medical applications of cord blood stem cells or the process of banking. Educational campaigns, potentially in collaboration with public health organizations or medical professionals, could demystify the process, highlight success stories, and underscore the long-term health security that cord blood storage can provide, thereby expanding the overall addressable market for the company's services in China.
What Opportunities Does CORBF Have?
- Increasing public awareness and acceptance of cord blood banking services in China.
- Advancements in regenerative medicine and stem cell therapies, expanding the potential uses of stored cord blood.
- Potential for strategic partnerships with healthcare providers to expand market reach within licensed regions.
- Technological improvements in cord blood processing and storage, enhancing service quality and efficiency.
What Threats Does CORBF Face?
- Changes in Chinese healthcare regulations or licensing policies that could impact operational scope or profitability.
- Intensified competition from other licensed cord blood banks or emerging alternative technologies.
- Economic downturns or public health crises in China that could reduce birth rates or discretionary spending on private banking services.
- Reputational risks associated with biological sample handling and long-term storage integrity.
What Are CORBF's Competitive Advantages?
- **Regulatory Barriers to Entry:** Operates under specific government licenses in designated regions of China, creating high barriers for new competitors.
- **Specialized Infrastructure:** Possesses and maintains sophisticated, high-cost cord blood banks with specialized equipment for testing, processing, and cryopreservation.
- **Established Operational History:** Has an established track record and operational presence in the Chinese market since its founding, building trust and brand recognition.
- **Niche Market Focus:** Specializes in a critical, high-value niche within the healthcare sector, focusing on a unique biological resource.
What Does CORBF Do?
Global Cord Blood Corporation, headquartered in Central, Hong Kong, is a prominent provider of umbilical cord blood storage and ancillary services exclusively within the People's Republic of China. The company, which was formerly known as China Cord Blood Corporation and rebranded in March 2018, has established itself as a key player in the specialized field of biological sample preservation. Its core operations revolve around offering comprehensive cord blood testing, meticulous processing, and secure long-term storage services. These services are provided under the direct instruction of individual subscribers, catering to families seeking to preserve their newborns' cord blood for potential future medical use. Beyond private banking, Global Cord Blood Corporation also plays a critical role in public health by testing, processing, and storing donated cord blood. This donated blood contributes to a public inventory, from which the company facilitates matching services for patients in need of hematopoietic stem cell transplants. As of March 31, 2022, the company strategically operates three state-of-the-art cord blood banks. These facilities are located in key economic and population centers: one in the expansive Beijing municipality, another in the economically vibrant Guangdong province, and a third in the dynamic Zhejiang province. This geographic footprint allows the company to serve a significant portion of the Chinese market, leveraging its specialized infrastructure and expertise. Global Cord Blood Corporation functions as a subsidiary of Blue Ocean Structure Investment Company Ltd., managing a workforce of 1202 employees dedicated to its specialized healthcare services.
What Products and Services Does CORBF Offer?
- Provides umbilical cord blood storage services to private subscribers.
- Offers cord blood testing and processing services for both private and donated samples.
- Operates three specialized cord blood banks in Beijing, Guangdong, and Zhejiang provinces, China.
- Stores donated cord blood for public use and facilitates matching services for patients.
- Manages the long-term cryopreservation of biological samples under strict conditions.
- Engages in the healthcare sector, specifically in medical diagnostics and research related to stem cells.
How Does CORBF Make Money?
- Generates revenue primarily through subscription fees for private umbilical cord blood storage services.
- Charges for initial testing and processing of cord blood samples.
- Receives fees for ongoing storage and maintenance of cord blood units.
- Provides matching services for donated cord blood, likely involving fees for access or related services to medical institutions.
- Operates under a licensed model within specific geographic regions in China, limiting direct competition.
What Industry Does CORBF Operate In?
Global Cord Blood Corporation operates within the highly specialized and regulated medical diagnostics and research industry, specifically focusing on umbilical cord blood banking in China. The global cord blood banking market is driven by increasing awareness of stem cell therapies, advancements in medical research, and a growing trend towards personalized medicine. In China, this industry is further shaped by specific regulatory frameworks and a vast population base, creating a unique market dynamic. Global Cord Blood Corporation's positioning as one of the licensed operators in key provinces (Beijing, Guangdong, Zhejiang) grants it a significant competitive advantage due to the high barriers to entry, including stringent licensing requirements and the substantial capital investment needed for specialized infrastructure. The competitive landscape in China is characterized by a limited number of licensed players, making market share acquisition and retention critical. The company's focus on both private subscriber services and public donation programs allows it to tap into different segments of the market, contributing to its stability within this niche healthcare sector.
Who Are CORBF's Key Customers?
- Prospective parents and families who choose to privately store their newborn's umbilical cord blood.
- Medical institutions and research facilities that utilize donated cord blood for transplants or research.
- Healthcare professionals who refer patients for cord blood banking services.
- Individuals and families seeking matching services for stem cell transplants from public cord blood banks.
FY2026 estForward Outlook
Wall Street analysts project Global Cord Blood Corporation revenue of about $727.2M for fiscal 2026, with EPS near $1.31.
F-Score 8/9Financial Health
Global Cord Blood Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.62 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 11%Key Financial Metrics
Return on equity for Global Cord Blood Corporation stands at 10.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.9%, showing how much profit it generates from its asset base. CORBF trades at a trailing price-to-earnings ratio of 1.57, below the Healthcare sector average of ~23x. Its free cash flow yield is 68.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 63.7%, the inverse of the P/E and a quick read on earnings relative to price.
Global Cord Blood Corporation (CORBF) Valuation Context
Valued at $127.35M, CORBF is classified as a micro-cap stock. Relative to its peer group, CORBF's quantitative score of 53/100 is below the peer average of 64/100.
Company Profile
Global Cord Blood Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Central, HK. The company is led by CEO Ting Zheng. CORBF has traded publicly since 2007.
CORBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see long-term value, a classic bullish signal.
- Community chatter highlights the company's strong market position in cord blood banking in China, a potentially lucrative market.
- Positive sentiment revolves around potential regulatory changes that could benefit the industry.
- The company's focus on expanding its service offerings beyond basic cord blood storage is perceived as a proactive growth strategy.
Bear Case
- Negative community sentiment focuses on concerns about competition from newer players in the cord blood banking space.
- There are worries about the long-term viability of the cord blood banking model as alternative stem cell sources gain traction.
- Some investors are skeptical about the company's ability to maintain market share given the evolving regulatory landscape.
- Concerns exist regarding the overall growth potential of the cord blood industry in China, given demographic shifts.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
CORBF Latest News
No recent news available for CORBF.
CORBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CORBF.
Price Targets
Wall Street price target analysis for CORBF.
CORBF MoonshotScore
What does this score mean?
The MoonshotScore rates CORBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ting Zheng
Chief Executive Officer
Ting Zheng serves as the Chief Executive Officer of Global Cord Blood Corporation, overseeing the company's extensive operations and strategic direction. Her background details, including specific career history, educational qualifications, and previous executive roles prior to her current position at Global Cord Blood Corporation, are not publicly disclosed in the provided information. She is responsible for managing the company's 1202 employees and ensuring the efficient operation of its three cord blood banks in China.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Ting Zheng's leadership are not detailed in the provided source data. Her role involves guiding the company's continued provision of umbilical cord blood storage and ancillary services, maintaining its operational footprint in Beijing, Guangdong, and Zhejiang provinces, and managing its workforce of 1202 employees. The company's consistent operation and financial metrics reflect ongoing management of its specialized healthcare services.
CORBF OTC Market Information
Global Cord Blood Corporation trades on the 'OTC Other' tier of the OTC market. This tier is typically for companies that do not meet the reporting standards of OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Companies in the 'OTC Other' tier may not be required to publish financial reports or may have limited public disclosure. This contrasts significantly with exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial reporting, corporate governance, and minimum share prices, ensuring a higher level of transparency and investor protection. The 'OTC Other' designation suggests a lower level of regulatory oversight compared to major exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Transparency:** The 'Unknown' disclosure status means investors may lack access to critical financial and operational information, making due diligence difficult.
- **Lower Liquidity:** Trading on the 'OTC Other' tier often results in lower trading volumes and wider bid-ask spreads, making it harder to buy or sell shares efficiently.
- **Regulatory Scrutiny:** OTC markets, particularly lower tiers, may be subject to less regulatory oversight compared to major exchanges, increasing potential for market manipulation or fraud.
- **Price Volatility:** Lower liquidity and limited information can contribute to higher price volatility, exposing investors to greater risk of significant price fluctuations.
- **Limited Analyst Coverage:** OTC stocks, especially those with limited disclosure, typically receive minimal to no coverage from institutional analysts, reducing available independent research.
- Verify the company's current operational status and any recent news from independent sources.
- Attempt to locate any available financial statements, even if not officially filed, from third-party data providers.
- Research the regulatory environment in China pertaining to cord blood banking and any recent changes.
- Assess the company's market position and competitive landscape within its licensed regions.
- Understand the implications of the 'OTC Other' tier and 'Unknown' disclosure status on investment risk.
- Evaluate the long-term prospects of the cord blood banking industry in China.
- Consider the potential for delisting or further restrictions on trading due to compliance issues.
- Operates three physical cord blood banks in specific, high-population regions of China (Beijing, Guangdong, Zhejiang).
- Provides a specialized and essential healthcare service (cord blood storage and ancillary services).
- Has a stated number of employees (1202), indicating a significant operational scale.
- Functions as a subsidiary of Blue Ocean Structure Investment Company Ltd., suggesting corporate backing.
- Formerly known as China Cord Blood Corporation, indicating a history and established presence in the sector.
Common Questions About CORBF (Healthcare)
What does Global Cord Blood Corporation do?
Global Cord Blood Corporation is a specialized healthcare company focused on umbilical cord blood banking and related services in the People's Republic of China. The company operates three licensed cord blood banks located in Beijing, Guangdong, and Zhejiang provinces. Its primary services include the collection, testing, processing, and long-term cryopreservation of umbilical cord blood. These services are offered to private subscribers who wish to store their newborn's cord blood for potential future medical use. Additionally, Global Cord Blood Corporation manages a public cord blood bank, accepting donated cord blood and providing matching services for patients requiring hematopoietic stem cell transplants. The company plays a crucial role in the specialized sector of regenerative medicine by preserving these vital biological resources.
What is the market position of Global Cord Blood Corporation in China?
Global Cord Blood Corporation holds a specific market position within the highly regulated Chinese cord blood banking industry. As of March 31, 2022, the company operates three licensed cord blood banks, strategically located in the populous and economically significant regions of Beijing, Guangdong, and Zhejiang. This licensed operational model provides a degree of market protection and establishes the company as a key provider in these areas. The Chinese market for cord blood banking is characterized by stringent regulatory oversight and high barriers to entry, meaning that companies like Global Cord Blood Corporation, with established infrastructure and licenses, benefit from a relatively stable competitive environment within their authorized territories. Its dual approach of serving both private subscribers and managing public donations further solidifies its comprehensive market presence.
What are the operational challenges for a cord blood bank like CORBF?
Operating a cord blood bank like Global Cord Blood Corporation involves several significant operational challenges inherent to the highly specialized nature of its business. Firstly, maintaining the integrity and viability of biological samples over decades requires state-of-the-art cryopreservation technology, continuous monitoring, and robust backup systems, demanding substantial capital expenditure and technical expertise. Secondly, adherence to stringent national and provincial healthcare regulations in China is paramount, necessitating ongoing compliance efforts and adaptability to potential policy changes. Thirdly, managing a large workforce of 1202 employees across three distinct facilities requires sophisticated logistical coordination and quality control to ensure consistent service delivery. Lastly, public education and trust-building are ongoing challenges, as the company must continuously inform prospective parents about the benefits and safety of cord blood banking to expand its subscriber base.
How does Global Cord Blood Corporation's OTC listing affect investors?
Global Cord Blood Corporation's listing on the 'OTC Other' tier of the OTC market, coupled with an 'Unknown' disclosure status, significantly impacts investors. This classification typically means the company is not subject to the same rigorous reporting and transparency requirements as stocks on major exchanges like NYSE or NASDAQ. Consequently, investors may face challenges in accessing timely and comprehensive financial information, making thorough due diligence more difficult. The 'OTC Other' tier often experiences lower trading volumes and wider bid-ask spreads, which can result in reduced liquidity. This means investors might find it harder to buy or sell shares quickly at a favorable price, potentially leading to increased transaction costs and greater price volatility. These factors collectively contribute to a higher investment risk profile compared to exchange-listed securities.
What are the financial characteristics of Global Cord Blood Corporation?
Global Cord Blood Corporation exhibits several notable financial characteristics based on the provided data. The company has a market capitalization of $127.35M, indicating its overall valuation. Its P/E ratio stands at 1.6, suggesting that the market values its earnings at a relatively low multiple. Operationally, the company demonstrates strong profitability with a gross margin of 85.3%, indicating efficient management of its direct costs of services. This high gross margin translates into a robust profit margin of 40.3%, signifying a substantial portion of its revenue is converted into net income. The company's Beta is -0.81, which suggests a historical tendency to move inversely to the broader market, potentially offering diversification benefits. Global Cord Blood Corporation does not pay a dividend.
What are the key factors to evaluate for CORBF?
Global Cord Blood Corporation (CORBF) holds an AI score of 53/100 (moderate). P/E: 1.6x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CORBF data refresh on this page?
CORBF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CORBF's recent stock price performance?
Global Cord Blood Corporation (CORBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence and operational licenses in key Chinese provinces (Beijing, Guangdong, Zhejiang). See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information for CEO background and track record is limited to name and employee count; specific achievements are not provided in the source data.
- Growth opportunities and catalysts are inferred from the company's business model and general industry trends due to a lack of specific forward-looking statements in the provided source data.
- Competitor information was not provided in the source data, hence the empty array for competitors.
- Word count requirements for several sections, especially growth opportunities and FAQs, necessitated detailed elaboration on the provided factual basis without introducing speculation.